High ratio of fasting blood sugar to HDL-C tied to CV adverse events, death in ACS patients: Study

For this purpose, the researchers performed a post hoc analysis using data from a pragmatic, stepped-wedge, cluster-randomized clinical trial. 11,284 individuals with ACS were subdivided into quartiles in accordance with their FG/HDL-C ratios.

The relationship between the FG/HDL-C ratio and short-term outcomes (major adverse cardiovascular events [MACEs] and cardiovascular [CV] death within 30 days) was evaluated using a multivariate logistic regression model, two-piecewise linear regression model, and generalized additive model (GAM). 

"The study showed that FG/HDL-C ratio may be used as an accessible, convenient, and economical biomarker of short-term outcomes in ACS patients," the authors concluded. "Close attention should be paid to ACS patients undergoing CABG and those aged < 75 years with a high FG/HDL-C ratio."

Reference:

Deng, S., Wang, Z., Zhang, Y. et al. Association of fasting blood glucose to high-density lipoprotein cholesterol ratio with short-term outcomes in patients with acute coronary syndrome. Lipids Health Dis 21, 17 (2022). https://doi.org/10.1186/s12944-021-01618-2